Introduction and Overview of MTC Diagnosis Challenges

Video

For High-Definition, Click

Moderator Ezra Cohen, MD, introduces a panel discussion on managing patients with medullary thyroid cancer (MTC) effectively in an endocrinology and oncology setting. The discussion includes perspectives from the leading experts and frontline practitioners Eric J. Sherman, MD, Steven I. Sherman, MD, R. Michael Tuttle, MD, and Lori J. Wirth, MD.

A variety of methods and guidelines have emerged to diagnose patients with MTC, explains Steven Sherman. In general, these tumors are diagnosed through fine needle aspiration or prospective screening as a result of familial MTC or MEN 2. Patients with these syndromes can be diagnosed in a preclinical state through genetic screening and biochemical assessments of the marker calcitonin, explains Steven Sherman.

As a rare disease, distinct challenges face the accurate diagnosis of patients with MTC, particularly the awareness of the disease. In general, these tumors present as common thyroid nodules that are noticed either by a primary care physician or by the patient, Tuttle notes. From here, patients are either referred to see an endocrinologist or directly to biopsy. Once biopsied, results are usually read as atypical or suspicious, since MTC is not generally the first thought. Once MTC is suspected, serum calcitonin can be utilized to confirm the diagnosis.

In some cases, primarily in Europe, the measurement of calcitonin is being recommended for every patient with a thyroid nodule, Tuttle notes. However, this approach has not been embraced in the US, due to false positive rates associated with hypoparathyroidism, Hashimoto’s thyroiditis, and proton pump inhibitors. Rather than testing all patients, specific symptoms can be utilized that suggest a diagnosis of MTC, explains Tuttle, such as the presence of a thyroid nodule and diarrhea.

Related Videos
Alessandro Villa, DDS, PhD, MPH
Arya Amini, MD
Anna Lee, MD, MPH
Adrianna Masters, MD, PhD,
Chul Kim, MD, MPH
Andrew Ip, MD
In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.
In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.
In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.
In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.